Contact Information

For further information about our program, please contact our Hematology/Medical Oncology Fellowship Coordinator, via email or at 980-442-6158.

General Overview

The Carolinas HealthCare System Levine Cancer Institute is an ACGME-Accredited three year combined Hematology and Medical Oncology Fellowship Program. Upon successful completion of the fellowship program, graduates will be board-eligible for Medical Oncology and Hematology. The fellowship program is accredited for a total of nine slots, and the program will have three fellows each year.

The goal of the Levine Cancer Institute Hematology/Medical Oncology Fellowship Program is to train outstanding physicians who will become leaders in a diverse range of domains, including patient care, education, clinical, patient-oriented outcome, and translational research. The innovative curriculum adheres to the principles and guidelines outlined by the ACGME and the national hematology and oncology societies, the American Society of Hematology and American Society of Clinical Oncology. It has been developed to educate fellows in the multidisciplinary care of oncologic and hematologic diseases, emphasizing the care and management of patients in the outpatient setting, and the understanding and adoption of the newest technologies in our rapidly advancing fields.

Fellows are given escalating levels of responsibility and independence in the management of patients with increasing experience. Our flexible curriculum design is intended to allow trainees to focus their fellowship on their individual career aspirations, whether it is in patient care or research. Through our program fellows should achieve excellence in the practice of Hematology and Oncology and acquire the skills necessary for productive careers in patient care, and independent research.

Back to top

A basic breakdown of activities by year is as follows:

Year 1:
  • Introduction to Hematology/Oncology
  • 4 months of outpatient oncology; 2 months of outpatient hematology
  • 4 months of inpatient hematology (includes 2 months of consults), and 1 month of inpatient oncology
Year 2:
  • 2 months of inpatient hematology (includes 1 month of consult), and 1 month of inpatient oncology
  • 1 month of outpatient hematology; 2 months of outpatient multidisciplinary oncology
  • 1 month of research
  • 5 months of elective (research or clinical), determined in conjunction with program directors
Year 3:
  • 1 month of outpatient oncology; 1 month of outpatient hematology
  • 10 months of elective (research or clinical), determined in conjunction with program directors

During the elective time, fellows may pursue research for up to 15 months. Thus, fellows may have up to 16 months of protected research time (aside from continuity clinic), if deemed appropriate and necessary after discussion with the program directors and research mentor. If their research project has been completed, and especially if fellows plan to pursue careers in clinical medicine, they may continue with further clinical rotations, which are organized in disease-specific and multidisciplinary rotations.

A distinct element of the LCI Hematology/Medical Oncology fellowship program is the emphasis on multidisciplinary care of patients with malignancies, as demonstrated in the second year multidisciplinary rotations in thoracic and breast cancers. During these rotations, fellows will primarily rotate with medical oncologists, but will also learn from surgeons, radiation oncologists, and other appropriate specialists, such as pulmonologists and genetic counselors. Fellows may participate in similar rotations in other malignancies during the elective time.

Back to top

Throughout Training

Fellows will have ½ day continuity clinic experiences throughout the three years (156 weeks) of fellowship, excepting vacation. During the first year of fellowship, fellows will spend six months in hematology clinic and six months in oncology clinic for their continuity. Towards the end of the first year of fellowship, fellows will then select the domain and physician with whom they will spend the continuity clinic during the second and third year of fellowship.
Fellows will have core curriculum lectures weekly during the fellowship. There is a multidisciplinary General Tumor Board each week, in which fellows are expected to be active participants. Also, each month there will a Fellows conference in which the fellows present on patients and topics of interest, a fellow-run journal club, a President’s conference, led by the President of the LCI with the fellows on various patient and general topics of interest, and a Patient Quality Improvement conference. Fellows are also expected to participate in monthly LCI Translational and Clinical Research conferences, and Oncology Grand Rounds.
In addition, each disease type has a weekly or every other week multidisciplinary tumor board, with medical oncologists, surgeons, radiation oncologist, radiologists, pathologists, and other specialists as appropriate. Fellows are expected to be active participants in these tumor boards when they rotate in those disease types, or their continuity patients or inpatients require further discussion regarding management.

Back to top

Locations

The Levine Cancer Institute was conceived as a true “Cancer Center Without Walls.” As such, the Levine Cancer Institute has many physicians and faculty members at many sites in North and South Carolina. These sites comprise a variety of socioeconomic areas and practice types providing fellows with exposure to the whole range of clinical care that practicing hematologists/oncologists may experience, including office-based practice, and hospital-based practice, in urban, suburban and rural settings.

Fellows will spend most of their time at the Carolinas Medical Center main campus, and Levine Cancer Institute-Morehead location. During their third year, in particular, fellows will have the opportunity to rotate at these different locations, including the following:

Back to top

Faculty Overview

Jimmy J Hwang, MD - Program Director
Jimmy Hwang, MD, FACP
Program Director

Dr. Hwang is the Director of the Hematology/Medical Oncology fellowship at the LCI, and the Chief of the GI Medical Oncology section, since joining the Carolinas Healthcare System Levine Cancer Institute in September of 2013. He received his medical degree from the University of Pittsburgh School of Medicine, and completed his hematology/medical oncology fellowship at the University of Pittsburgh Cancer Institute. He was a member of the faculty at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center from 2001 to 2013. He served as the Program Director of the Fellowship Program in Hematology/Medical Oncology from 2006 to 2013. Dr. Hwang is a Clinical Associate Professor of the University of North Carolina at Chapel Hill, School of Medicine.

Daniel Carrizosa, MD - Associate Program Director
Daniel Carrizosa, MD
Associate Program Director

Dr. Carrizosa is one of the Associate Program Directors in the Hematology/Medical Oncology fellowship at the LCI. He received his medical degree at the University of North Carolina, Chapel Hill School of Medicine, and completed his hematology/medical oncology fellowship at the University of North Carolina Memorial Hospital. He has active research interests in thoracic malignancies and health care disparities.

Julie Fisher, MD - Associate Program Director
Julie Fisher, MD
Associate Program Director

Dr. Fisher is one of the Associate Program Directors in the Hematology/Medical Oncology fellowship at the LCI. She received her medical degree from the Medical University of South Carolina, and completed her fellowship I hematology/medical oncology at the Columbia University Medical Center. Her areas of interest focus on breast cancer.

Asim Amin, MD, PhD - Key Clinical Faculty
Asim Amin, MD, PhD
Key Clinical Faculty

Dr. Amin is the co-director of the Immunotherapy program at LCI. He received his medical degree from the King Edward Medical College in Lahore, Pakistan, and a PhD in immunology from the University of California, Davis. He completed his fellowship in hematology/medical oncology at the Georgetown University Medical Hospital Lombardi Cancer Center. He was subsequently a member of the faculty at the Lombardi Cancer Center. He has been widely published in melanoma, renal cell cancer and immunotherapy.

Edward Copelan, MD, FACP - Key Clinical Faculty
Edward Copelan, MD, FACP
Key Clinical Faculty

Dr. Copelan is the Chair of the Department of Hematologic Oncology and Blood Disorders at the Levine Cancer Institute. He received his medical degree from Tufts University School of Medicine, and completed his fellowship in hematology and medical oncology at the Ohio State University Hospitals, with an additional fellowship in bone marrow transplantation from the University of California Los Angeles. He has been on the faculty and director of bone marrow transplantation at the Ohio State University and then Cleveland Clinic, also becoming the director of the Leukemia program at the latter.

Ometayo Fasan, MBBS, MRCP - Key Clinical Faculty
Ometayo Fasan, MBBS, MRCP
Key Clinical Faculty

Dr. Fasan is the Director of apheresis at LCI. He received his medical degree from the University of Lagos, and completed his Hematology/Oncology fellowship at Temple University Hospital, and then joined the faculty at the Temple University Hospital and Fox Chase Cancer Center. He is a Clinical Assistant Professor of Medicine at the University of North Carolina, Chapel Hill. His research interests include lymphomas and leukemias.

Jonathan Gerber, MD - Key Clinical Faculty
Jonathan Gerber, MD
Key Clinical Faculty

Dr. Gerber is the Director of the Leukemia section at LCI. He received his medical degree and completed his fellowship in Hematology from the Johns Hopkins School of Medicine, and subsequently joined the faculty at Johns Hopkins. He is a Clinical Assistant Professor of Medicine at the University of North Carolina, Chapel Hill.

Nilanjan Ghosh, MD, PhD - Key Clinical Faculty
Nilanjan Ghosh, MD, PhD
Key Clinical Faculty

Dr. Gerber is the Director of the Leukemia section at LCI. He received his medical degree and completed his fellowship in Hematology from the Johns Hopkins School of Medicine, and subsequently joined the faculty at Johns Hopkins. He is a Clinical Assistant Professor of Medicine at the University of North Carolina, Chapel Hill.

Michael Grunwald, MD - Key Clinical Faculty
Michael Grunwald, MD
Key Clinical Faculty

Dr. Grunwald received his medical degree from the Johns Hopkins School of Medicine, and completed his hematology/medical oncology fellowship at Johns Hopkins. Dr. Grunwald is a Clinical Assistant Professor of Medicine at the University of North Carolina, Chapel Hill. He is extensively published in acute myeloid leukemia.

Mary Ann Knovich, MD - Key Clinical Faculty
Mary Ann Knovich, MD
Key Clinical Faculty

Dr. Knovich is the Director of Bleeding Disorders at LCI. She received her medical degree from the Pennsylvania State University College of Medicine. She completed her fellowship in Hematology/Medical Oncology at the Wake Forest University Baptist Medical Center, and then joined the faculty there, rising to the rank of Associate Professor, and was the Medical Director of the Comprehensive Hemophilia Diagnostic and Treatment Center, Adult Sickle Cell Program, and Apheresis Unit, before joining LCI. She has given many lectures, and been extensively published in iron disorders, sickle cell and non-malignant hematologic diseases.

David Miller, MD - Key Clinical Faculty
David Miller, MD
Key Clinical Faculty

Dr. Miller is the Director of Non-malignant hematology at LCI, and is the Chairman of the Center of Excellence for Thrombosis and Hemostasis; of the Blood and Tissue Committee and of the Blood Conservation committee of the Carolinas HealthCare System. He received his medical degree from the Medical College of Georgia, and completed his fellowship in Hematology and Oncology from the Duke University Medical Center.

Ashley Sumrall, MD - Key Clinical Faculty
Ashley Sumrall, MD
Key Clinical Faculty

Dr. Sumrall received her medical degree from the University of Mississippi Medical Center. She completed her Hematology/Medical Oncology fellowship at the University of Mississippi Medical Center, then an additional Neuro-Oncology Fellowship at the Duke University Medical Center. She has been extensively published on central nervous system malignancies. She is a Clinical Assistant Professor of Medicine at the University of North Carolina, Chapel Hill.

Antoinette Tan, MD, M.H.Sc. - Key Clinical Faculty
Antoinette Tan, MD, M.H.Sc.
Key Clinical Faculty

Dr. Tan is the Chief of Breast Medical Oncology, and Co-Director of the Phase I program at LCI. She received her medical degree from the Robert Wood Johnson Medical School. She completed her Oncology fellowship at the National Cancer Institute, then joined the faculty at the Rutgers Cancer Institute of New Jersey, and has been the Chair of the American Society of Clinical Oncology Cancer Education Committee.

Saad Usmani, MD, FACP. - Key Clinical Faculty
Saad Usmani, MD, FACP
Key Clinical Faculty

Dr. Usmani is the Director of Plasma Cell Disorders at LCI and the Director of Clinical Research in Hematologic Malignancies at LCI. He received his medical degree from Allama Iqbal Medical College. He completed his Hematology and Medical Oncology Fellowship at the University of Connecticut, then joined the faculty of the University of Arkansas. He is a Clinical Associate Professor of Medicine at the University of North Carolina, Chapel Hill.

Other Faculty of Note:

Back to top

Close